# Supplementary Material

Supplementary Table 1. Patient and disease characteristics at baseline (n=48).

|  |  |  |
| --- | --- | --- |
| Age (years) | Mean (SD) | 62.2 (9.4) |
| Median | 62.5 |
| Min, Max | 45, 84 |
| ECOG performance status, n (%) | 0 | 28 (58) |
| 1 | 18 (38) |
| 2 | 2 (4) |
| Tumour site at baseline, n (%) | Bone | 38 (79) |
| Brain | 2 (4) |
| Breast | 5 (10) |
| Liver | 11 (23) |
| Lung | 15 (31) |
| Lymph nodes | 9 (19) |
| Skin | 5 (10) |
| Time between primary diagnosis and baseline (years) | Mean (SD) | 7.7 (5.9) |
| Median | 5.5 |
| Min, Max | 1, 22 |
| Time between disease recurrence and baseline (years) | Mean (SD) | 3.0 (3.4) |
| Median | 2.3 |
| Min, Max | 0, 18 |
| No. of sites in the metastatic setting, n (%) a | 1 | 23 (48) |
| 2 | 16 (33) |
| 3 | 6 (13) |
| 4 | 3 (6) |
| No. of previous lines of treatment in the metastatic setting | Mean (SD) | 1.8 (1.4) |
| Median | 1 |
| Min, Max | 0, 7 |
| Previous treatment in the metastatic setting, n (%) | None | 5 (10) |
| Chemotherapy | 10 (21) |
| Endocrine treatment | 43 (90) |

n = Number of patients, SD = Standard deviation

a Breast was a site of disease progression in 11 patients (23%)

# Supplementary Figure 1

Supplementary Figure 1. Kaplan–Meier curves for progression-free survival and overall survival (n=48). A. Progression-free survival. B. Overall survival.